Obesity, Abdominal

A case study on how DelveInsight helped a pharma client navigate the evolving metabolic dysfunction-associated steatohepatitis (MASH) landscape with actionable market intelligence LAS VEGAS, March 13, 2025 /PRNewswire/ -- DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market in key Asian countries. Formerly known as Non-Alcoholic Steatohepatitis (NASH), MASH was officially renamed in 2023 by leading liver disease authorities, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), to reflect its metabolic origins better. The client sought to evaluate MASH prevalence, MASH patient burden, existing and emerging therapies for MASH, and market entry feasibility in China, India, Japan, South Korea, and Southeast Asian nations. Understanding MASH grade- and severity-specific patient pools, treatment adoption, and competitive dynamics was crucial to shaping their market entry and product positioning strategy. With decades of expertise in Pharma Market Assessments, DelveInsight employed rigorous epidemiological research, competitive intelligence, and strategic forecasting to equip the client with actionable insights. Our comprehensive analysis provided a clear picture of MASH treatment trends, market gaps, and the potential opportunities for innovative therapies. MASH is a rising global health concern, particularly in Asia, where factors such as ethnicity, obesity, and metabolic syndrome contribute to high prevalence rates. According to DelveInsight, there were approximately 42 million prevalent cases of MASH in the 7MM (US, EU5, and Japan) in 2023, with 15 million diagnosed cases, a figure projected to increase significantly by 2034. In Asia, MASH prevalence varies significantly between rural and urban populations. Japan accounted for 2.5 million diagnosed cases in 2023, while India exhibited a higher prevalence in urban areas (17–25%) compared to rural regions (10%). Other Southeast Asian countries, such as Sri Lanka, Malaysia, and Singapore, show prevalence rates ranging from 5% to 35%. Additionally, in South Korea, obesity and abdominal obesity rates reached 36% and 24%, respectively, highlighting a growing risk factor for MASH. Currently, only one drug is approved for MASH treatment . On March 14, 2024, the FDA approved REZDIFFRA for NASH patients with moderate to severe fibrosis (F2-F3), setting a new benchmark for efficacy and safety. Its acceptance is expected to accelerate future NASH treatments, with clinical trials likely expanding to Southeast Asia. Beyond Rezdiffra, several companies are advancing therapies in the pipeline, including I nventiva Pharma, Novo Nordisk, Cirius Therapeutics, Akero Therapeutics, 89bio, Boehringer Ingelheim/Zealand Pharma, Galectin Therapeutics, Viking Therapeutics, Eli Lilly, Pfizer, Merck & Co./Hanmi Pharmaceutical, Gilead Sciences, and others. For the latest insights, explore DelveInsight's updated MASH Market Report . A data-driven Market Size and Share Assessment is vital for strategic decision-making in today's competitive pharmaceutical landscape. DelveInsight's market analysis helps companies identify target patient populations, assess treatment landscapes, and analyze emerging therapies to uncover growth opportunities. DelveInsight enables pharmaceutical firms to make informed decisions, optimize strategies, and secure a strong market presence by providing market forecasting, adoption trends, and competitive positioning insights. With MASH gaining attention as a high-burden disease with significant unmet needs, understanding market dynamics is critical for companies looking to make a meaningful impact. DelveInsight's Data-Driven Market Assessment Methodology for Unlocking MASH Opportunities To help our client navigate the MASH market, DelveInsight employed a multifaceted research and strategic analysis approach, combining epidemiological insights, competitive intelligence, and market forecasting. Our methodology included the following key steps: Market Dynamics Evaluation – The current MASH treatment landscape was analyzed across each target country, assessing market share data for existing therapies and forecasting the adoption of treatments in development. Competitor Analysis & Market Entry Assessment – An in-depth competitor landscape study was conducted, identifying key companies developing MASH drugs and evaluating the feasibility of market entry in each region. Strategic Product Positioning – To differentiate the client's product in a symptom-management-dominated market, a treatment-based approach was emphasized, ensuring better alignment with healthcare providers and patient needs. Grade-Specific Patient Focus – Based on the client's request, research was prioritized on grade-specific patient populations, offering targeted recommendations by understanding disease progression and unmet needs at different stages. Strategic Outcomes of DelveInsight's Market Size and Share Assessment for MASH By integrating rigorous data analysis with strategic insights, DelveInsight provided the client with a clear, actionable roadmap for market entry, competitive positioning, and long-term success in the evolving MASH market. DelveInsight's rigorous epidemiological research provided the client with a detailed assessment of the MASH (formerly NASH) burden across key Asian markets. By analyzing prevalence data across different disease grades and severity levels, we equipped the client with actionable insights into the target patient population, enabling informed strategic planning. Our market dynamics evaluation gave the client a comprehensive view of the existing treatment landscape, including market share insights and future adoption forecasts for emerging therapies. This allowed the client to identify growth opportunities, optimize product positioning, and make data-driven market entry decisions. Through competitive intelligence and feasibility assessments, we pinpointed key players and potential market entry barriers in each target country. These insights helped the client anticipate challenges, refine market penetration strategies, and gain a competitive edge. By prioritizing grade-specific patient segmentation, we provided tailored recommendations, helping the client better understand patient needs at various disease stages. This enabled them to align their strategy with real-world clinical and commercial dynamics, ultimately strengthening their position in the evolving MASH market. Curious about how the MASH landscape is evolving? Let DelveInsight be your guide . Get in touch today for expert insights and strategic solutions! Market Size and Share Assessment Services: DelveInsight provides a 360-degree market landscape analysis, delivering 10-year epidemiology-driven market forecasts. Our expertise offers precise insights into emerging therapies' current and projected market share, helping stakeholders navigate evolving treatment landscapes. By integrating epidemiology-based models, emerging trends, competitive dynamics, and unmet needs, we empower businesses to craft data-driven strategies and identify lucrative opportunities. Whether it's pipeline analysis, pricing strategies, epidemiology-driven forecasting, or competitive benchmarking, DelveInsight delivers actionable intelligence tailored to your strategic goals. Competitive Intelligence Services Tailored to Gastroenterology Domain: DelveInsight's competitive intelligence services deliver real-time, precise insights across therapeutic domains, with gastroenterology being one of our key areas of expertise. We provide in-depth analysis of advancements across both prevalent and rare conditions, including MASH, Primary Sclerosing Cholangitis, Ulcerative Colitis, and Barrett's Esophagus. Our services track competitor pipelines, clinical trial progress, regulatory shifts, and patent landscapes, offering a comprehensive view of the evolving gastroenterology market. By leveraging these insights, stakeholders can identify emerging threats, seize growth opportunities, and craft strategic moves to stay ahead in this dynamic space. Conference Coverage Services: DelveInsight's Conference Coverage Services offer a thorough analysis of outcomes from major gastroenterology events like WCOG, Euro-Global Gastroenterology Conference, ICGH, ICGDD, and ICCGVG. This detailed examination provides businesses with essential insights for competitive intelligence and market trend forecasting, supporting the formulation of future strategies. R&D Analysis: DelveInsight's skilled research and development analyst specializes in the complexities of different indications, offering essential insights and advice to clients aiming to advance in research and development. They utilize a methodical assessment approach, aligned with industry norms, to track the progress of each drug in both pre-clinical and clinical stages. DelveInsight's comprehensive reports are crafted to reduce uncertainties and highlight overlooked areas, providing organizations with timely and strategic intelligence. Why Choose DelveInsight? DelveInsight's Market Assessment Services provide data-driven insights and competitive intelligence to help pharmaceutical companies navigate evolving market landscapes. With 10-year forecasts, drug uptake analysis, competitive benchmarking, and customized market evaluations, we deliver precise projections for both emerging and established markets. Our expertise in epidemiology modeling, primary intelligence, and data analytics ensures clients gain a clear, strategic understanding of their therapy's potential and competitive positioning. Covering the 7MM region and beyond, DelveInsight equips stakeholders with actionable intelligence to drive informed decision-making and commercial success. Get in touch today to leverage our expertise and stay ahead in the competitive market! Contact us for a personalized consultation. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

REDWOOD CITY, CA, USA I December 30, 2024 I Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing’s syndrome). Corcept’s NDA is based on positive results from the pivotal GRACE trial and confirmatory evidence from the Phase 3 GRADIENT and long-term extension studies and a Phase 2 study in hypercortisolism. Patients in these studies who received relacorilant experienced improvements in a wide array of hypercortisolism’s signs and symptoms, with an acceptable safety burden. Notably, there were no instances of drug-induced adrenal insufficiency, hypokalemia or QT prolongation – serious adverse events that can arise in patients taking currently approved medications – and no adverse events associated with activity at the progesterone receptor, such as endometrial thickening or vaginal bleeding. “Relacorilant’s combination of efficacy and safety give it the potential to become the standard of care for the medical treatment of patients with hypercortisolism,” said Joseph Belanoff, MD, Corcept’s Chief Executive Officer. “Our commitment to the health of patients with hypercortisolism is unwavering. We are optimistic that relacorilant will be of great benefit to them.” About Relacorilant Relacorilant is a selective cortisol modulator that binds to the glucocorticoid receptor but not to the body’s other hormone receptors. Corcept is studying relacorilant in a variety of serious disorders in addition to endogenous hypercortisolism (Cushing’s syndrome), including ovarian, adrenal and prostate cancer. Relacorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. Relacorilant has orphan drug designation in the United States and the European Union for the treatment of Cushing’s syndrome. About Hypercortisolism (Cushing’s Syndrome) Hypercortisolism is caused by excessive activity of the hormone cortisol. Symptoms vary, but most patients experience one or more of the following manifestations: hypertension, central obesity, elevated blood sugar and difficult-to-control type 2 diabetes, severe fatigue and weak muscles. Irritability, anxiety, depression and cognitive disturbances are common. Hypercortisolism can affect every organ system and can be lethal if not treated effectively. About Corcept Therapeutics For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients with a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ® , the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com. SOURCE: Corcept Therapeutics

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 30, 2024-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing’s syndrome). Corcept’s NDA is based on positive results from the pivotal GRACE trial and confirmatory evidence from the Phase 3 GRADIENT and long-term extension studies and a Phase 2 study in hypercortisolism. Patients in these studies who received relacorilant experienced improvements in a wide array of hypercortisolism’s signs and symptoms, with an acceptable safety burden. Notably, there were no instances of drug-induced adrenal insufficiency, hypokalemia or QT prolongation – serious adverse events that can arise in patients taking currently approved medications – and no adverse events associated with activity at the progesterone receptor, such as endometrial thickening or vaginal bleeding. “Relacorilant’s combination of efficacy and safety give it the potential to become the standard of care for the medical treatment of patients with hypercortisolism,” said Joseph Belanoff, MD, Corcept’s Chief Executive Officer. “Our commitment to the health of patients with hypercortisolism is unwavering. We are optimistic that relacorilant will be of great benefit to them.” About Relacorilant Relacorilant is a selective cortisol modulator that binds to the glucocorticoid receptor but not to the body's other hormone receptors. Corcept is studying relacorilant in a variety of serious disorders in addition to endogenous hypercortisolism (Cushing’s syndrome), including ovarian, adrenal and prostate cancer. Relacorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. Relacorilant has orphan drug designation in the United States and the European Union for the treatment of Cushing’s syndrome. About Hypercortisolism (Cushing’s Syndrome) Hypercortisolism is caused by excessive activity of the hormone cortisol. Symptoms vary, but most patients experience one or more of the following manifestations: hypertension, central obesity, elevated blood sugar and difficult-to-control type 2 diabetes, severe fatigue and weak muscles. Irritability, anxiety, depression and cognitive disturbances are common. Hypercortisolism can affect every organ system and can be lethal if not treated effectively. About Corcept Therapeutics For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients with a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com. Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations and are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties are set forth in our SEC filings, which are available at our website and the SEC’s website. In this press release, forward-looking statements include statements concerning: the results of our Phase 2, GRACE, GRADIENT, and long-term extension studies; relacorilant’s efficacy, safety and other clinical attributes and its potential to receive regulatory approval and become a standard-of-care treatment for patients with endogenous hypercortisolism; regulatory oversight of relacorilant and the scope, pace and outcome of its NDA submission; relacorilant’s acceptance and use by physicians and patients and its commercial prospects; and the scope and protective power of relacorilant’s orphan drug designation and our intellectual property. We disclaim any intention or duty to update forward-looking statements made in this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20241230947567/en/ Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Source: Corcept Therapeutics Incorporated